ALLOCYTE PHARMACEUTICALS AG
- AlloCyte Pharmaceuticals AG (AlloCyte) is a privately held Swiss company founded in November 2011. - AlloCyte develops innovative small molecule drugs for severe immune-mediated diseases. - AlloCyte targets one of the most powerful families of drug targets, integrins, via a novel pharmacological mechanism. - AlloCyte’s activities are financed by private investors and public funds including the Swiss Commission for Technology and Innovation (CTI).
ALLOCYTE PHARMACEUTICALS AG
Social Links:
Industry:
Information Technology Pharmaceutical
Founded:
2011-11-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.allocyte-pharmaceuticals.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Danish Server Location
Similar Organizations
Glactone Pharma AB
Glactone Pharma AB is a privately held Swedish biotech company founded in 2012
Johnson Matthey
Johnson Matthey is an international speciality chemicals company, founded almost 200 years ago in London.
Noorik Biopharmaceuticals
Noorik Biopharmaceuticals is a privately owned drug development company based in Basel, Switzerland.
Official Site Inspections
http://www.allocyte-pharmaceuticals.com Semrush global rank: 11.92 M Semrush visits lastest month: 143
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "AlloCyte Pharmaceuticals AG"
Home | AlloCyte Pharmaceuticals AG
AlloCyte Pharmaceuticals AGSee details»
AlloCyte Pharmaceuticals AG - LinkedIn
AlloCyte Pharmaceuticals AG | 48 followers on LinkedIn. Next generation allosteric integrin therapeutics. | AlloCyte Pharmaceuticals AG is a Swiss-based company discovering, developing and ...See details»
AlloCyte Pharmaceuticals AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AlloCyte Pharmaceuticals AG of Basel, BASEL-STADT. Get the latest business insights from Dun & …See details»
AlloCyte Pharmaceuticals AG - VentureRadar
"AlloCyte Pharmaceuticals AG is the privately held Swiss company translating its proprietary next-generation small molecule integrin pharmacology into therapies of transformative potential for …See details»
AlloCyte Pharmaceuticals AG - Tech Park Basel
Sep 20, 2023 AlloCyte Pharmaceuticals AG AlloCyte Pharmaceuticals AG is a privately held company discovering and developing next generation allosteric small molecule integrin …See details»
AlloCyte Pharmaceuticals AG – Swiss Biotech
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework …See details»
AlloCyte Pharmaceuticals AG - Company Profile and News
Company profile page for AlloCyte Pharmaceuticals AG including stock price, company news, executives, board members, and contact informationSee details»
AlloCyte Pharmaceuticals AG | Companies | Mindmaps
AlloCyte Pharmaceuticals AG is a Swiss company established in 2011 that focuses on creating small molecule drugs to treat severe immune-mediated diseases. They target integrins, a …See details»
AlloCyte Pharmaceuticals - Products, Competitors, Financials, …
About AlloCyte Pharmaceuticals AlloCyte Pharmaceuticals is involved in allosteric integrin therapeutics within the pharmaceutical industry. The company is engaged in the development …See details»
AlloCyte Pharmaceuticals - IT History Society
AlloCyte Pharmaceuticals AG (AlloCyte) is a privately held Swiss company founded in November 2011. - AlloCyte Pharmaceuticals AG (AlloCyte) is a privately held Swiss company founded in …See details»
About 2-alt | My Site - allocyte-pharmaceuticals.com
AlloCyte Pharmaceuticals AG is a Swiss-based company discovering, developing and commercializing next generation allosteric small molecule integrin modulators to address …See details»
AlloCyte Pharmaceuticals AG :: Switzerland :: OpenCorporates
Free and open company data on Switzerland company AlloCyte Pharmaceuticals AG (company number 1040181), Hochbergerstr., 60C, Basel, 4057See details»
AlloCyte Pharmaceuticals AG in Basel - Kontakt und Auskünfte | Lixt
AlloCyte Pharmaceuticals AG in Basel | Aktiv | Gegründet 2011 | Management: Christoph Daniel Maier, Gabriele Weitz-Schmidt | Letzte Änderung: 02.07.2021See details»
AlloCyte Pharmaceuticals AG Company Insights, Tech Stack, and ...
Find useful insights on AlloCyte Pharmaceuticals AG’s company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at AlloCyte …See details»
AlloCyte Pharmaceuticals AG - Basel, Switzerland - bionity.com
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product …See details»
Contact us-alt | My Site - allocyte-pharmaceuticals.com
In case you recognize a potential match of AlloCyte’s next generation small molecule allosteric integrin recalibratory technology with your company’s strategic portfolio interest, please feel …See details»
LFA-1 Inhibitor (AlloCyte) - Drug Targets, Indications, Patents
May 7, 2025 LFA-1 Inhibitor (AlloCyte): a ITGAL&ITGB2 antagonists Drug, Initially developed by AlloCyte Pharmaceuticals AG, Now, its global highest R&D status is Preclinical, Mechanism: …See details»
Handelsregister: AlloCyte Pharmaceuticals AG, Basel - Tiger.ch
Jul 2, 2021 Handelsregister Eintrag der Firma AlloCyte Pharmaceuticals AG in Basel / BSSee details»
AlloCyte Pharmaceuticals AG - Basel, Schweiz - bionity.com
Start-up AlloCyte Pharmaceuticals AG Hochbergerstrasse 60C 4057 Basel Schweiz allocyte-pharmaceuticals.com Profil Produkte Kontakt aufnehmenSee details»
Incyte Appoints Bill Meury Chief Executive Officer; Hervé …
1 day ago Prior to that, he was CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Before Karuna, Mr. Meury spent more than two …See details»